Comments Off

|

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at …

MONT-SAINT-GUIBERT, Belgium, May 18, 2012 /PRNewswire/ —

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

Andr Terzic, M.D., Ph.D, Director at Center of Regenerative Medicine, Mayo Clinic, the co-lead investigator on the trial, will present new final follow up data on the Company’s stem cell therapy for heart failure, C3BS-CQR-1, which is based on “Cardiopoiesis” proprietary technology. The presentation will be held on Sunday, May 20th in Belgrade, Serbia.

Dr. Christian Homsy, CEO of Cardio3 BioSciences, said: “Being selected to present the final follow-up data in the late breaking clinical trial session at this prestigious cardiology congress highlights the quality of our technology and reiterates our belief in C3BS-CQR-1 as a potential treatment for patients with heart failure, a condition with a significant unmet medical need. We look forward to advancing the product into Phase III.”

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Center Aalst, Belgium.

The Company’s lead product candidate C3BS-CQR-1 is an innovative pharmaceutical product consisting of autologous cardiac progenitor stem cells. C3BS-CQR-1 is based on ground breaking research conducted at Mayo Clinic that allowed discovery of cardiopoiesis, a process to mimic in adult stem cells the natural signals triggered in the early stages of life during the cardiac tissue development. Cardio3 BioSciences has also developed C-Cath, the next-generation injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information contact:

Cardio3 BioSciences: http://www.c3bs.com Dr Christian Homsy, CEOTel : +32-10-39-41-00 Anne Portzenheim, Communication Manager aportzenheim@c3bs.com

View original post here:
Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at …

admin, May 18th 2012

Tags: , , , , , , , , , , , ,
Posted in Cardiac Stem Cells

Comments Off

|

Mary Ann Liebert releases BioResearch Open Access journal

The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. The first issue is available on the BioResearch Open Access website at http://www.liebertpub.com/biores.

The premier issue includes research papers and a brief report from the U.S., U.K., Germany, and Korea on diverse topics such as tissue engineering, stem cells, HIV, and genetics. Forthcoming papers for the second issue include genetics, xenotransplantation, nuclear transfer, and cardiac research.

The Journal is under the leadership of Editor-in-Chief Jane Taylor, PhD, Senior Research Fellow, MRC Centre for Regenerative Medicine, University of Edinburgh, and seasoned journal editors as Section Editors, including James M. Wilson, MD, PhD, University of Pennsylvania; Antonios G. Mikos, PhD, Rice University; Professor Sir Ian Wilmut, OBE FRS FRSE, University of Edinburgh; Peter C. Johnson, MD, Scintellix, LLC, Raleigh, NC; Aubrey D.N.J. de Grey, PhD, SENS Foundation, Cambridge, UK; Alan J. Russell, PhD, Carnegie Mellon University; Thomas Hope, PhD, Northwestern University; Ganes C. Sen, PhD, Cleveland Clinic Foundation; Bruce A. Sullenger, PhD, Duke University Medical Center; Graham C. Parker, PhD, Wayne State University School of Medicine; Carol Shoshkes Reiss, PhD, New York University; Stephen C. Ekker, PhD, Mayo Clinic, Rochester, MN; John B. West, MD, PhD, University of California, San Diego; David L. Woodland, PhD, Chief Scientific Officer, Keystone Symposia on Molecular and Cellular Biology; Stephen Higgs, PhD, Kansas State University; Eugene Kolker, PhD, Seattle Children’s Hospital; and Domenico Grasso, PhD, PE, DEE, University of Vermont.

View post:
Mary Ann Liebert releases BioResearch Open Access journal

admin, May 18th 2012

Tags: , , , , , , , , , , , , , ,
Posted in Cardiac Stem Cells

Comments Off

|

Possible Diabetes Diagnosis For 53 Million Americans By 2025

May 16, 2012

Connie K. Ho for RedOrbit.com

A new report in Population Health Management (PHM) discusses the Diabetes 2025 Model for the U.S., its predictions on the increase in the number of people who have diabetes, and how this rise could impact the health care system. The researchers explained their predictions for specific states and population subgroups with 15-year projections. Based on the Diabetes 2025 Model, the authors believe that diabetes (mainly type 2) will affect 53.1 million Americans by 2025; its an increase of 64 percent from 2010.

The project was created to make information on projections of diabetes more widely available. The researchers also hoped to make the data easily accessible both online and in person. The Diabetes 2025 Model was created based off the most current U.S. Census Bureau forecasts.

According to the report, the incidence and prevalence of diabetes has risen from 1990. The study was done by Dr. William Rowley and Dr. Clement Bezold with the Institute for Alternative Futures. The report was published in PHM, which focuses on strategies for improving policies and systems of health care quality, access, and outcome. It also provides research on social, cultural, economic, and environmental factors that may affect health care systems and practices.

Diabetes is now a national security issue as it threatens all aspects of our nations well-being, noted Journal Editor-in-Chief Dr. David B. Nash, Dean of the Jefferson School of Population Health, in a prepared statement.

The report stated that the Diabetes 2025 Model can be used to show the benefits of changing lifestyle habits and particular interventions in helping to reduce the diabetes epidemic.

Early appropriate treatment makes a significant difference in preventing major complications and reducing premature death, but it does not cure the disease. Early detection of prediabetes, in conjunction with lifestyle changes, can reduce the number of people with diabetes, wrote authors in the report.

Furthermore, researchers believe that changes in lifestyle could lead to saving millions in health care costs.

If our health care system were able to persuade 50% of Americans with prediabetes every year to seriously change their lifestyles for the rest of their lives, the result could be about 4.7 million fewer cases of diabetes in 2025 with a cumulative savings of about $300 billion. Yet even if this happened, there would still be 48.4 million Americans living with diabetes, explained authors in the report. These sobering numbers suggest that it would take dramatic lifestyle changes on the part of all of society to prevent prediabetes in the first place in order to produce a dramatic decline by 2025. More realistically, it shows that we will continue to have a huge burden of diabetes to contend with for the foreseeable future.

Read more:
Possible Diabetes Diagnosis For 53 Million Americans By 2025

admin, May 18th 2012

Tags: , , , , , , , , ,
Posted in Diabetes

Comments Off

|

Mid-Atlantic Waterproofing Rides To Stop Diabetes and Donates $50,000 to the American Diabetes Association at the …

COOKSVILLE, Md., May 17, 2012 /PRNewswire/ — Mid-Atlantic Waterproofing, a basement waterproofing and foundation repair company, had over 50 riders and volunteers in the American Diabetes Association’s (www.diabetes.org) Tour de Cure cycling event on May 5, 2012. The event was to help raise funds to change the future of diabetes and help stop this devastating disease.

(Photo: http://photos.prnewswire.com/prnh/20120517/CL08829 )

Close to 750 cyclists from around the region gathered at the Gary J. Arthur Community Center to participate in the event. They joined more than 55,000 other cyclists and volunteers from across the country who also participated. Individuals and teams composed of co-workers, family and friends took the ride of their life by helping raise funds for the nearly 26 million Americans with diabetes. The Tour de Cure is designed for anyone from the occasional to the experienced cyclist.

“Many people will participate in the Tour de Cure for the stimulating competition, camaraderie and physical cycling challenge. But the real reward comes in knowing that every mile they ride and every dollar they raise brings us that much closer to stopping this disease that affects 300,000 people in our community,” said Kathy Rogers, executive director of the American Diabetes Association Maryland regional office. “With diabetes growing at near-epidemic proportions, the need for funds has never been so great,” Kathyadded. With this event we raise awareness of diabetes and its challenges. But most importantly, we raise money for research to find a cure.

At the conclusion of the ride, Ed Fennell, President of Mid-Atlantic Waterproofing of MD, Inc, proudly gave the ADA staff a check for $50,000. “What a great feeling to be part of such a worthy cause,” Fennell said.

Since 1965, Mid-Atlantic Waterproofing has specialized in solving wet basement and crawl space problems. They are experts in structural foundation repair and keeping basements and crawl spaces dry. “For the Driest Basement In Town”

The various locations serve MD,DC,VA,WV,PA,DE,NJ,NY & CT. Past donations have been made to the American Lung Association, Doctors Without Borders, The Packard Center for ALS research, the USO, Catholic Relief Services, and the United Way.

www.basements.com

Read the rest here:
Mid-Atlantic Waterproofing Rides To Stop Diabetes and Donates $50,000 to the American Diabetes Association at the …

admin, May 18th 2012

Tags: , , , , , , , , , , ,
Posted in Diabetes

Comments Off

|

Diabetes testing call from concerned MP

Nigel Evans has urged people to ask their GP to test them for diabetes.

Read more:
Diabetes testing call from concerned MP

admin, May 18th 2012

Tags: , , , ,
Posted in Diabetes

Comments Off

|

Diabetes can't slow Reed

Home Sports Pro Loading

Published: 5/18/2012 – Updated: 23 minutes ago

BY RACHEL LENZI BLADE SPORTS WRITER

First, the doctors told Ryan Reed he had type 1 diabetes. Then, they told him he would never be able to be a competitive race car driver.

Ryan Reed didn’t listen to the diagnosis. He told himself that there had to be another way to pursue his dream.

“I started doing research on what I could do,” said Reed, who is from Bakersfield, Calif. “I didn’t understand the disease, but to give up altogether would be ridiculous. I needed to understand what was holding me back from driving.”

But Reed, 18, sought out doctors who answered his questions and offered him guidelines — not just on how to compete safely and how to maintain his insulin and glucose levels, but how to live with a disease that, according to the National Diabetes Information Clearinghouse, afflicts more than 18.8 million Americans, including at least 215,000 under the age of 20.

In his first year of driving on the ARCA circuit, Reed drives for Venturini Motorsports and enters Sunday’s Menards 200 at Toledo Speedway tied for fourth with Chris Buescher in the standings.

Diagnosed in February, 2011, Reed acknowledges he’s still in the “honeymoon” phase of the disease, as he hasn’t had any of the adverse effects of diabetes.

The first time Reed knew something was wrong was when he was behind the wheel, leading the bulk of a 200-lap late-model race.

See the original post here:
Diabetes can't slow Reed

admin, May 18th 2012

Tags: , , , , , , , ,
Posted in Diabetes

Comments Off

|

Diabetes Can Take a Toll on Your Emotions

THURSDAY, May 17 (HealthDay News) — Many people know diabetes — both type 1 and type 2 — can take a serious toll on physical health. But these blood-sugar disorders also can affect your emotions and, in turn, your emotions can wreak havoc on your diabetes control.

See the original post:
Diabetes Can Take a Toll on Your Emotions

admin, May 18th 2012

Tags: , , , , , , , , , ,
Posted in Diabetes

Comments Off

|

Personalized Primary Care Membership Service HiTouch Health Launches Website, Open for Business

HiTouch Health offers a new business model for fee-based primary careSan Francisco, CA (PRWEB) May 18, 2012 HiTouch Health, a new membership-based medical service that provides highly personalized primary care services to patients in partnership with their personal physician, today announced the launch of its website – hitouchhealth.com.HiTouch Health brings a unique customer experience and an …

Read the rest here:
Personalized Primary Care Membership Service HiTouch Health Launches Website, Open for Business

admin, May 18th 2012

Tags: , , , , , , , ,
Posted in Personalized Medicine

Comments Off

|

A new dimension to DNA and personalized medicine of the future

(Phys.org) — By investigating the existence of an unusual four-stranded structure of DNA in human cells, scientists have opened the door to novel cancer therapeutics and a new era for personalised medicine.

When Watson and Crick discovered the double helix structure of DNA in 1953, they declared they had found the secret of life. However, as in all pursuits of science, the story did not end there. Less than 60 years later, a team led by chemist Professor Shankar Balasubramanian and cancer biologist Professor Steve Jackson has found that an unusual four-stranded configuration of DNA also forms at sites across the human genome in living cells.

Although known about by scientists for decades, the structure was considered to be something of a structural curiosity rather than a feature found in nature. It forms in regions of DNA that are rich in one of its building blocks, guanine (G), when a single strand of the double-stranded DNA loops out and doubles back on itself, forming a four-stranded handle in the genome.

G-quadruplexes have been known to occur at the ends of chromosomes in the regions known as telomeres, but it wasnt until a strong association had been noticed with genes responsible for cell proliferation that Balasubramanian and others began to suspect that G-quadruplexes might be a potential target for cancer therapy. If you synthesize a quadruplex-binding molecule and put it into cancer cells, it can impair the growth of these cells, he said. Weve come such a long way from thinking that we understand the genome and it appeared that this structure could tell us something new.

This video is not supported by your browser at this time.

Protecting the genetic code

At the heart of the new discovery is an innovative way of locating the structures in living cells and then capturing them for further examination. The scientists discovered that when pyridostatin binds to G-quadruplex DNA it causes a double-strand break in the double helix when the cell tries to replicate and copy its genes: Pyridostatin binding to G-quadruplexes is a major impediment to copying the genome so if a cell tries to replicate, this will generate breaks in the DNA, said Jackson.

Over the years, Jacksons lab has found that there are certain proteins in the cell that act as molecular policemen, patrolling the nucleus of the cell looking for damaged DNA. If they detect damage, they start making repairs, and at the same time set off alarm signals to alert the rest of the cell that theres a problem.

When there is no DNA damage, these molecular policemen are distributed evenly throughout each cells nucleus. But when cells are treated with pyridostatin, they congregate in specific locations on the DNA, indicating regions of damage, and showing up as dots under the microscope. The field really jumped on the idea that these dots represent telomeres that have G-rich sequences and in vitro have the potential to form G-quadruplexes, said Jackson. But we stained the dots for telomere proteins and found there was only a small amount of overlap. So clearly, this pyridostatin compound is inducing DNA damage in lots of other places, and we were faced with the issue: if they are not telomeres, what are they?

This confirmed an earlier finding in Balasubramanians lab by Julian Huppert, then a PhD student, who devised a computational search algorithm to map out every spot in the entire human genome that had potential to fold into a G-quadruplex. He found there were close to 350,000 of them.

Continue reading here:
A new dimension to DNA and personalized medicine of the future

admin, May 18th 2012

Tags: , , , , , , , , ,
Posted in Personalized Medicine

Comments Off

|

Bionest Publishes Landmark Article on Quantitative Financial Analysis of Personalized Medicine Strategies

NEW YORK & PARIS–(BUSINESS WIRE)–

Bionest Partners, a premier strategy and management consulting firm for the life science industries, and a recognized leader in personalized medicine (PM) strategy consulting, announces the publication of an article in a recent issue of Nature Reviews Drug Discovery (NRDD).

This article, a result of the FDA Personalized Medicine Initiative a consortium effort across the FDA, industry and academia analyzes the key value drivers of PM development and commercialization strategies, elucidates a comprehensive approach for evaluating these strategies, and employs various modeling tools to support decision-making.

The publication of this article is timely, given the significant and increasing commitment to PM by pharmaceutical companies, highlighted by recent PM launches such as Xalkori and Zelboraf, and notable PM candidates in the pipeline including T-DM1 (Roche/Genentech, for Her2 positive breast cancer), Dabrafenib (GSK, for BRAF V600E positive melanoma), and Afatinib (BI, for EGFR mutation positive NSCLC).

Dr. Sean X. Hu, Head of Bionest USA and Managing Partner, North America, a co-lead author of the article, and the only representative from the management consulting industry serving in the FDA PM Initiative consortium, points out that the key to successful decision-making around whether and how best to incorporate biomarkers into drug development and commercialization depends on an in-depth understanding of multiple disciplines: the underlying science, clinical trial design and development paths, regulatory requirements, partnership and coordination between drug and diagnostic partners, drug and diagnostic commercialization, pricing and market access, and decision-making in the context of many uncertainties. This article identifies key value drivers and risk factors associated with PM drug and diagnostic development and commercialization. In addition, it presents a coherent approach to tie these factors together, and describes the use of financial modeling tools to arrive at such metrics as risk-adjusted net present value (NPV) and return on investment (ROI) metrics that companies often use to make key investment decisions for their products.

Dr. Federico Goodsaid, who co-authored the article while at the FDA and is currently VP of Strategic Regulatory Intelligence at Vertex Pharmaceuticals, adds: This consortium, with the participation of FDA, academic institutions and many pharmaceutical companies, was a unique opportunity to advance the field of PM by tackling one of the bottlenecks in optimizing decision-making on PM development and commercialization strategies how to quantify the commercial value of a potential biomarker-based strategy. Sean and his team made this work possible with their knowledge about PM, advanced modeling tools, and rigor in the application of decision-analysis methods to assess the value of PM strategic options and to account for their corresponding risks and uncertainties.

Bionest is attending the upcoming ASCO 2012 Annual Meeting in Chicago, June 1 5, 2012. For further discussions with Dr. Hu and his Bionest team on PM strategies, either at ASCO 2012 or another occasion, please contact Dr. Rachel Laing (rlaing@bionest.com).

Bionest is a powerhouse in PM strategy consulting, experienced in a broad spectrum of project types, from corporate level PM business models, commercialization capability building, R&D and commercialization business processes, and organizational structure, to development and commercialization strategies for individual drug assets and companion diagnostics.

In addition, Bionest has been driving thought leadership on PM, with many articles published or in development on the strategic, commercial and technical aspects of PM, including a recent article in collaboration with the Personalized Medicine Coalition (PMC) in the December 2011 supplement issue of Science which describes the approaches for optimization of PM decision-making.

For more details, please visit www.bionest.com, and navigate to section Strategic/Practices/Personalized Medicine Strategy.

Continue reading here:
Bionest Publishes Landmark Article on Quantitative Financial Analysis of Personalized Medicine Strategies

admin, May 18th 2012

Tags: , , , , , , , , ,
Posted in Personalized Medicine
« Older Posts

Subscribe to RSS feed